New swallowing test could spot hidden risks in SMA patients
NCT ID NCT04773470
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed study looked at how well a camera test called FEES (flexible endoscopic evaluation of swallowing) can detect and track swallowing problems in people with spinal muscular atrophy (SMA). Researchers studied 79 SMA patients of different types and ages, using several standard scales to measure swallowing safety and function. The goal was to improve diagnosis and monitoring of dysphagia, which is common in SMA and can lead to serious complications.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to better, standardized ways to detect and monitor swallowing problems in SMA, helping guide treatment decisions.
- What could go wrong
- This is a completed diagnostic study, not a treatment trial. The findings may not change clinical practice immediately and need further validation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SPINAL MUSCULAR ATROPHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University Hospital Giessen and Marburg, Campus Giessen
Giessen, Hesse, 35392, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can gene therapy help babies with SMA reach milestones? a Real-World review
- School transitions put to the test for children with a rare muscle disease
- Horseback therapy may boost movement and breathing in kids with Muscle-Weakening disease
- Newborn screening study aims to catch rare diseases at birth
- Gene therapy trial aims to halt Muscle-Wasting disease
- Higher dose of spinraza tested in SMA patients who already tried risdiplam